Summary
The current status of iodine 131-radiolabeled monoclonal antibody G250 (mAb G250) in renal-cell carcinoma (RCC) is described. This mAb recognizes a tumor-associated antigen that is expressed on the cell surface of almost all RCC but is not expressed on normal tissues, with the exception of gastric mucosa and larger bile ducts. On the basis of these favorable characteristics, this mAb seemed a prime candidate for clinical investigations. Preclinical animal studies and ex vivo perfusion experiments in tumor-bearing kidneys showed excellent targeting of mAb G250 to RCC tumors. Supported by these investigations, a phase I study was initiated to define the imaging and biodistribution characteristics of 131I-labeled mAb G250 in RCC patients. Specific localized of [131I]-mAb G250 to G250-antigen-positive primary and metastatic RCC was observed. In several patients, [131I]-mAb G250 imaging revealed thus far unrecognized, i.e., occult, disease. Values obtained for [131I]-mAb G250 uptake, relative as well as absolute, were among the highest reported for tumor biopsies obtained 8 days after intravenous mAb administration. The specific localization and high accumulation encouraged us to begin a phase I/II radiotherapy trial with [131I]-mAb G250. The maximal tolerable dose was reached at 90 mCi/m2 [131I]-mAb G250. In the subsequent phase I/II radiotherapy study, we observed stable disease in a great number of patients as well as minor responses in a small number of patients. Multiple treatments seemed necessary to achieve better response rates. However, anti-mouse responses prevented multiple dosing with the murine mAb G250. Therefore, we developed a chimeric version of mAb G250 (cG250), in which constant regions of the mouse immunoglobulin have been exchanged for human immunoglobulin regions. A phase I clinical trial with cG250 is ongoing and very encouraging. The general imaging and targeting characteristics of cG250 seem comparable with those of murine mAb G250. In the near future the (radio)therapeutic possibilities of this promising mAb will be investigated.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Bander NH, Finstad CL, Cordon-Cardo C, et al (1989) Analysis of a mouse monoclonal antibody that reacts with a specific region of the human proximal tubule and subsets renal cell carcinomas. Cancer Res 4:6774–6780
Buist MR, Kenemans P, Kamp GJ van, Haisma HJ (in press) Minor human antibody response to mouse and chimeric monoclonal antibodies after a single i.v. infusion in ovarian carcinoma patients: comparison of five assays. Cancer Immunol Immunother
Chiou R-K, Woodson M (1988) Monoclonal antibody-targeted radiotherapy (MRT) for renal cell carcinoma: evaluations of its potentials and limitations (abstract 1743). Proc Am Assoc Cancer Res 29:438
Chiou R-K, Vessella RL, Elsen MK, et al (1985) Localization of human renal cell carcinoma xenografts with a tumor-preferential monoclonal antibody. Cancer Res 45:6140–6146
Divgi CR, Bander NH, Scott AM, et al (1994) Phase I radioimmunotherapy trial of I-131 labeled monoclonal antibody G250 in metastatic renal cancer (abstract 2999). Proc Am Assoc Cancer Res 35:503
Finstad CL, Cordon-Cardo C, Bander NH, et al (1985) Specificity analysis of mouse monoclonal antibodies defining cell surface antigens of human renal cancer. Proc Natl Acad Sci USA 82:2955–2959
Goldenberg DM (1988) Targeting of cancer with radiolabeled antibodies: prospects for imaging and therapy. Arch Pathol Lab Med 112:580–586
Goldenberg DM (1991) Current status of cancer imaging with radiolabeled antibodies. Antibody Immunoconjugates Radiopharm 4:517–524
Kochevar J (1987) A renal cell carcinoma neoplastic antigen detectable by immunohistochemistry is defined by a murine monoclonal antibody. Cancer 60:2031–2036
Köhler G, Milstein C (1975) Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256:495–497
Larson SM (1987) Lymphoma, melanoma, colon cancer: diagnosis and treatment with radiolabeled monoclonal antibodies. The 1986 Eugene P. Pendergrass New Horizons Lecture. Radiology 165:297–304
Larson SM (1990) Clinical radioimmunodetection, 1978–1988: overview and suggestions for standardization of clinical trials. Cancer Res 50:892S-898S
LoBuglio AF, Wheeler RH, Trang J, et al (1989) Mouse/human chimeric monoclonal antibody in man: kinetics and immune response. Proc Natl Acad Sci USA 86:4220–4224
LoBuglio AF, Meredith R, Wheeler RH, et al (1991) Chimeric monoclonal antibody studies in colorectal cancer. In: Epenetos AA (ed) Monoclonal antibodies. Chapman and Hall, Cambridge, pp 291–295
Luner SJ, Ghose T, Chatterjee S, et al (1986) Monoclonal antibodies to kidney and tumor-associated surface antigens of human renal cell carcinoma. Cancer Res 46:5816–5820
Mach JP, Pelegrin A, Buchegger F (1991) Imaging and therapy with monoclonal antibodies in non-hematopoietic tumors. Curr Opin Immunol 3:685–693
Morrison SL (1985) Transfectomas provide novel chimeric antibodies. Science 229:1202–1207
Morrison SL, Johnson MJ, Herzenberger LA, Oi VT (1984) Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. Proc Natl Acad Sci USA 81:6851–6855
Oosterwijk E, Ruiter DJ, Hoedemaeker PJ, et al (1986) Monoclonal antibody G250 recognizes a determinant present in renal-cell carcinoma and absent from normal kidney. Int J Cancer 38:489–494
Oosterwijk E, Ruiter DJ, Wakka JC, et al (1986) Immunohistochemical analysis of monoclonal antibodies to renal antigens: application in the diagnosos of renal cell carcinoma. Am J Pathol 123:301–309
Oosterwijk E, Bander NH, Divgi CR, et al (1993) Antibody localization in human renal cell carcinoma: a phase I study of monoclonal antibody G250. J Clin Oncol 11:738–750
Palme DF, Berkopec JM, Elson MK, et al (1988) Dosimetry and immunotherapy using monoclonal antibody (MoAb) A6H 131-iodine conjugates: radiobiological consequences and effect of escalating dosages (abstract 1706). Proc Am Assoc Cancer Res 29:428
Sands H, Jones PL, Shah SA, et al (1988) Correlation of vascular permeability and blood flow with monoclonal antibody uptake by human Clouser and renal cell xenografts. Cancer Res 48:188–193
Tagliabue E, Canevari S, Menard S, et al (1984) Human renal antigen defined by a murine monoclonal antibody. J Natl Cancer Inst 73:363–369
Van Dijk J, Oosterwijk E, Van Kroonenburgh MJPG, et al (1988) Perfusion of tumor-bearing kidneys as a model for scintigraphic screening of monoclonal antibodies. J Nucl Med 29:1078–1082
Van Dijk J, Zegveld ST, Fleuren GJ, et al (1991) Localization of monoclonal antibody G250 and bispecific monoclonal antibody CD3/G250 in renal-cell carcinoma xenografts: relative effects of size and affinity. Int J Cancer 48:738–743
Vaughan ATM, Anderson P, Dykes PW, et al (1986) Limitations to the killing of tumours using radiolabelled antibodies. Br J Radiol 60:567–578
Vaughan ATM, Bradwell AR, Dykes PW, et al (1986) Illusions of tumour killing using radiolabelled antibodies. Lancet I:1492–1493
Vessella RL (1991) Radioimmunoconjugates in renal cell carcinoma. In: Debruyne FMS, Bukowski RM, Pontes JE, De Mulder PHH (eds) Immunotherapy of renal cell carcinoma. Springer, Berlin Heidelberg New York, pp 38–46
Vessella RL, Moon TD, Chiou R-K, et al (1985) Monoclonal antibodies to human renal cell carcinoma: recognition of shared and restricted tissue antigens. Cancer Res 45:6131–6139
Vessella RL, Chiou RK, Grund FM, et al (1987) Renal cell carcinoma (RCC) phase I–II trials with 131–1 labeled monoclonal antibody A6H: imaging and pharmacokinetic studies (abstract 1525). Proc Am Assoc Cancer Res 28:480
Vessella RL, Palme DF, Berkopec JM, et al (1988) Radiotherapy of a human renal cell carcinoma (RCC) xenograft: comparison between single fraction monoclonal antibody (MoAb) A6H 131-iodine conjugates and single fraction X-ray external beam irradiation (abstract 1707). Proc Am Assoc Cancer Res 29:429
Wessels BW, Vessella RL, Palme DF, et al (1989) Radiobiological comparison of external beam radiation and radioimmunotherapy in renal cell carcinoma xenografts. Int J Radiat Oncol Biol Phys 17:1257–1263
Winter G, Milstein C (1991) Man-made antibodies. Nature 349:293–299
Yoshida SO, Imam A (1989) Monoclonal antibody to a proximal nephrogenic renal antiben: immunohistochemical analysis of formalin-fixed, paraffin-embedded human renal cell carcinomas. Cancer Res 49:1802–1809
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Oosterwijk, E., Debruyne, F.M.J. Radiolabeled monoclonal antibody G250 in renal-cell carcinoma. World J Urol 13, 186–190 (1995). https://doi.org/10.1007/BF00184877
Issue Date:
DOI: https://doi.org/10.1007/BF00184877